Academic Journal
Q1Medicine in Drug Discovery
About Medicine in Drug Discovery
Medicine in Drug Discovery is a scholarly journal published by Elsevier B.V.. SCImago 2025 lists it in Q1, with an SJR of 1.145 and H-index of 28.
Coverage: 2019-2026. Research categories: Drug Discovery (Q1); Pharmacology (Q1); Pharmacology (medical) (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Computational Drug Discovery Methods; RNA Interference and Gene Delivery; COVID-19 Clinical Research Studies; Nanoparticle-Based Drug Delivery; SARS-CoV-2 and COVID-19 Research; Advanced biosensing and bioanalysis techniques.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Therapeutic capabilities of naturally-derived p38 MAPK inhibitors for protecting the cerebrovascular system in severe SARS‑CoV‑2 infection
Mohammad Sheibani, Vasiliki Epameinondas Georgakopoulou, Maryam Mohammadi, Elaheh Abdollahi et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100257Harnessing QSAR and machine learning for the design of hepatocellular carcinoma inhibitors; experimental validation of the cytotoxicity of new compounds against HepG2 cells
Saba Ali, Ismail Dwi Putra, Ayokanmi Joseph Aremu, Peerada Jit-aree et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100260Natural products triggering non-apoptotic regulated cell death in lung cancer: A systematic review focusing on pyroptosis, with insights into cuproptosis and necroptosis
Rano Zhankina, Amin Tamadon, Nadiar M. Mussin, Myltykbay Rysmakhanov et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100263Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection
Chutatip Limkunakul, Palakorn Srinithiwat, Madhuros Thienmanee, Peerapon Vatunyootawewat et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100262Phenanthrene and dihydrophenanthrene derivatives from Vanda curvifolia with cytotoxic activity against glioblastoma cells
Sanith Sri Jayashan, Chattarika Pengdee, Al Arofatus Naini, Siriporn Jungsuttiwong et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100264Rhinacanthins from Rhinacanthus nasutus inhibit the Plasmodium falciparum mitochondrial cytochrome bc1 complex revealed by chemical genetic and in silico studies
Yuwathida Sunghanghwa, Parichat Prommana, Beow Keat Yap, Roonglawan Rattanajak et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100261Cyanobacterial peptides and polyketides: biosynthetic basis, structural diversity and therapeutic relevance
Abhishek Chauhan, Anuj Ranjan, Neelam Mishra, Hardeep Singh Tuli et al.
2026-08 · DOI: 10.1016/j.medidd.2026.100259Efficacy and safety of difluprednate for macular edema management: a systematic review and meta-analysis
Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan
2026-08 · DOI: 10.1016/j.medidd.2026.100265A monoterpenoid dihydrochalcone derivative isolated from Conamomum rubidum sensitizes erlotinib-mediated lung cancer cell death by suppressing STAT3/Bcl-2 signaling
Iksen Iksen, Chayaporn Jitsayreerat, Chavisa Klanbunchum, Hien Minh Nguyen et al.
2026-05 · DOI: 10.1016/j.medidd.2026.100254The effects of patent term extension on new drug patent protection in China, Europe, and the United States
Hai-Long Zhang, Yongxia Li
2026-05 · DOI: 10.1016/j.medidd.2026.100252Psychedelics; an untapped therapeutic niche: a narrative review in the future of cancer pain management
Maxine Min Chien Yap, Yasir Marwan Abdalla Omer, Yu Xuan Cheng, Wei Qi Chan et al.
2026-05 · DOI: 10.1016/j.medidd.2026.100256Dendrophenol Mitigates Inflammatory Sickness Behaviors and Maintains CNS Function in Murine Models
Hasriadi Hasriadi, Peththa Wadu Dasuni Wasana, Boonchoo Sritularak, Opa Vajragupta et al.
2026-05 · DOI: 10.1016/j.medidd.2026.100255Proteomic research in clinical samples of cardiovascular diseases
Yuntao Liang, Abdallah Iddy Chaurembo, Francis Chanda, Baraka Simon Mayaba et al.
2026-05 · DOI: 10.1016/j.medidd.2026.100253Intravenous and oral NOAEL doses of the new PrC-210 aminothiol in swine and dose equivalency in humans to enable clinical trials
William E. Fahl, Bryan L. Fahl, Aaron M. Dingle
2026-02 · DOI: 10.1016/j.medidd.2026.100248Machine learning based analysis of the risks of combination aspirin and rivaroxabane antithrombotic therapy with nonsteroid anti-inflammatory drugs after arthroplasty
Vladimir U. Emelianov, Sergey A. Khripunov, Evgeniya A. Mikishanina, Nikolai S. Nikolaev et al.
2026-02 · DOI: 10.1016/j.medidd.2025.100243Green Remedies: Pharmacological potential of phytonutrients for combatting air pollution-related respiratory diseases
Shobna L. Thuraisingam, Irene Heijink, Bey-Hing Goh, Yoon-Yen Yow et al.
2026-02 · DOI: 10.1016/j.medidd.2025.100235Toward peptide-based protein replacement in fragile X syndrome: Evaluating the N-tat strategy
Oliver A. Kent
2026-02 · DOI: 10.1016/j.medidd.2025.100244A rapid at-line LC-QTOF-MS/MS based targeting and guided isolation approach uncovers 2-methoxy-1,4-naphthoquinone from Impatiens balsamina Linn. as an anti-Malassezia agent
Weerapong Juntachai, Kantarawee Khayhan, Piyakaset Suksathan, Sathid Aimjongjun et al.
2026-02 · DOI: 10.1016/j.medidd.2026.100251Energy-based method for designing aptamers to target phosphatidylcholine
Fatima Alharbi, Hamed Alsulami, Suliman AlOmar, Md. Ashrafuzzaman et al.
2026-02 · DOI: 10.1016/j.medidd.2026.1002473D printing in drug delivery: emerging technologies, clinical translation, and the future of personalized medicine
Bellarmin Michael, Nandhini Jayaprakash, Nithyasree Munivel, Dharshini Jaisankar et al.
2026-02 · DOI: 10.1016/j.medidd.2025.100242Reviews
Community Reviews
Version History
September 25, 2026 at 7:50 am
September 25, 2026